Interview on National Public Radio with Jim Joyce, CEO of Aethlon Medical and Executive Chairman of Exosome Sciences. Its blood test appears to identify CTE – Chronic Traumatic Encephalopathy – in retired NFL players. The interview is quite informative as ...
Read More »
Results will add to Published Data Involving Candidate Biomarker to Identify & Monitor CTE Researchers with Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company, today announced plans to initiate a clinical study ...
Read More »
from Streetwise Reports – Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James “Jim” Joyce shares the ...
Read More »
from Neurology Advisor by Alicia Ciccone Researchers may have uncovered a way to detect chronic traumatic encephalopathy (CTE) in living individuals with a blood test that detects plasma exosomal tau. The preliminary results were published in the Journal of Alzheimer’s ...
Read More »
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc., announced recently that it has agreed to participate in a clinical research study to establish methods for detecting and diagnosing chronic traumatic encephalopathy (CTE) during life as well as ...
Read More »
Source: Gail Dutton of The Life Sciences Report SAN FRANCISCO, CA – December 23, 2015 (Investorideas.com stocks newswire) Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (AEMD), is pioneering the potential use of an exosome-based biomarker to diagnose chronic ...
Read More »
SAN DIEGO, PRINCETON, N.J. and BOSTON, Sept. 26, 2014 /PRNewswire/ — Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical collaboration with the Boston University (BU) CTE Center has been established to ...
Read More »
A new type of liquid biopsy for solid tumors based on analyzing exosomes from the blood is being tested at Thomas Jefferson University. Thomas Jefferson University announces a partnership with Exosome Sciences Inc. to evaluate a novel liquid biopsy platform ...
Read More »
Viable tumor cells actively release vesicles into the peripheral circulation and other biologic fluids, which exhibit proteins and RNAs characteristic of that cell. Researchers from Exosome Sciences, Inc demonstrated the presence of these extracellular vesicles of tumor origin within the peripheral ...
Read More »
SAN DIEGO and PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ — Aethlon Medical, Inc. (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed ...
Read More »
Exosome RNA Exosome RNA Research & Industry News
